Reaction
Myasthenic Syndrome reporting signals
As of the last recalculation, Myasthenic Syndrome appears in 752 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is TERAZOSIN HYDROCHLORIDE (PRR 63.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Terazosin Hydrochloride | 20 | 63.9 | 64.1 |
| Human Immunoglobulin G | 28 | 39.0 | 39.0 |
| Pembrolizumab | 123 | 38.5 | 38.5 |
| Pemetrexed | 25 | 33.3 | 33.4 |
| Rocuronium Bromide | 13 | 31.1 | 31.1 |
| Pemetrexed Disodium | 38 | 29.0 | 29.0 |
| Ipilimumab | 41 | 27.7 | 27.8 |
| Botulinum Toxin Type A | 12 | 27.2 | 27.2 |
| Nivolumab | 78 | 24.8 | 24.8 |
| Atezolizumab | 28 | 20.7 | 20.7 |
| Asenapine Maleate | 6 | 19.3 | 19.3 |
| Lovastatin | 17 | 18.7 | 18.7 |
| Carboplatin | 64 | 15.2 | 15.2 |
| Durvalumab | 8 | 11.0 | 11.0 |
| Abiraterone | 5 | 10.2 | 10.2 |